Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has provided an update.
TempraMed Technologies reported that more than 275 physicians across the United States are now recommending its VIVI Cap device through FrontrowMD, a leading physician engagement and education platform. This physician-driven model embeds TempraMed’s solution into clinical workflows, leveraging trusted medical voices to address the under-recognized risk of temperature exposure on medication effectiveness.
The FrontrowMD partnership, launched in December 2025, supports TempraMed’s broader commercialization strategy across pharmacy, direct-to-consumer, and enterprise channels. By scaling patient education and adoption through clinical endorsement, the company strengthens its positioning as a standard-of-care adjunct for temperature-sensitive medications and reinforces B2C demand generation and professional credibility nationwide.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company focused on innovative, temperature-controlled medication storage solutions. Its patented, FDA-registered thermal insulation devices, including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, protect temperature-sensitive medications without batteries or external power, serving patients and providers across North America, Europe, and Asia.
Average Trading Volume: 61,118
Learn more about VIVI stock on TipRanks’ Stock Analysis page.